Macular Degeneration Treatment Market Size, Share, Growth, and Industry Analysis, By Type (Lucentis, Eylea, Avastin, Others), By Application (Hospitals, Eye Clinics, Others), Regional Insights and Forecast to 2034

Macular Degeneration Treatment Market Overview

The Macular Degeneration Treatment Market size was valued at USD 6386.12 million in 2025 and is expected to reach USD 9065.62 million by 2034, growing at a CAGR of 3.6% from 2025 to 2034.

The Macular Degeneration Treatment Market is structured around a global patient base of approximately 196 million individuals affected by age-related macular degeneration (AMD), with projections indicating nearly 288 million cases by 2040. Wet AMD represents 10% to 15% of total AMD cases yet contributes to nearly 80% of severe central vision loss incidents. Anti-VEGF therapies account for more than 85% of total prescribed treatments in the Macular Degeneration Treatment Market. Globally, over 25 million intravitreal injections are administered annually for AMD management. Approximately 60% of treated patients are aged above 70 years, supporting sustained Macular Degeneration Treatment Market Growth and long-term therapeutic demand.

In the United States, over 11 million individuals live with AMD, including nearly 1.5 million diagnosed with advanced stages. Approximately 200,000 new wet AMD cases are reported annually. More than 6 million anti-VEGF injections are performed each year across 50 states. Nearly 75% of treated patients are aged above 75 years, reflecting demographic concentration. Around 80% of eligible patients receive Medicare-supported therapy. Over 2,000 retina specialty clinics actively administer intravitreal injections, each managing an average of 1,200 to 1,800 AMD patients annually, strengthening the Macular Degeneration Treatment Market Size and Macular Degeneration Treatment Market Share in the USA.

• 

  Download Free sample to learn more about this report.

Key Findings

• Key Market Driver:65% geriatric population exposure, 80% severe vision loss linked to wet AMD, 85% anti-VEGF prescription dominance, 70% long-term therapy continuation beyond 12 months, 60% patient pool aged above 70 years.
• Major Market Restraint:30% therapy discontinuation within 24 months, 25% missed injection appointments annually, 20% patient anxiety incidence, 15% rural specialist access limitation, 10% reduction in visual acuity due to non-adherence.
• Emerging Trends:45% pipeline focus on extended dosing, 35% gene therapy development, 28% biosimilar penetration expansion, 22% reduction in injection frequency innovations, 18% AI-driven diagnostic integration growth.
• Regional Leadership:40% North America share, 30% Europe share, 22% Asia-Pacific share, 8% Middle East & Africa share, 70% of advanced therapies concentrated in developed regions.
• Competitive Landscape:60% market controlled by top 3 manufacturers, 45% prescriptions dominated by 2 brands, 70% global trials led by 5 companies, 50% R&D investment allocated to retinal therapeutics.
• Market Segmentation:85% anti-VEGF utilization, 10% biosimilar contribution, 5% emerging therapies, 50% hospital-based injections, 40% eye clinic procedures, 10% other healthcare settings.
• Recent Development:35% pipeline assets in Phase III, 20% approvals reducing injection frequency, 25% biosimilar launches between 2023-2025, 15% gene therapy clinical progression.

Macular Degeneration Treatment Market Latest Trends

The Macular Degeneration Treatment Market Trends indicate that nearly 60% of new wet AMD patients are shifted to 8–12 week dosing regimens compared to traditional 4-week intervals. Around 45% of retina specialists report transitioning more than 50% of their patient base to longer-acting anti-VEGF therapies. Biosimilars represent approximately 12% of global prescriptions, with adoption increasing by 7% over 3 years. Gene therapy programs targeting sustained VEGF suppression have expanded by 40% since 2022, with over 15 active clinical trials globally.

Real-world evidence demonstrates that 30% to 35% of patients achieve ≥15-letter visual acuity gain at 12 months with consistent treatment. More than 25 million injections are delivered annually worldwide. Optical coherence tomography (OCT) systems capable of 70,000 A-scans per second are used in over 85% of retina clinics for disease monitoring. Teleophthalmology screening initiatives have expanded by 20% in developed markets, detecting early AMD in 18% of screened individuals aged above 60 years, supporting Macular Degeneration Treatment Market Outlook and Macular Degeneration Treatment Market Insights for B2B stakeholders.

Macular Degeneration Treatment Market Dynamics

DRIVER

Increasing aging population and AMD prevalence.

Globally, 703 million individuals are aged 65 years or older, representing nearly 9% of the global population. AMD prevalence rises to 12% among individuals older than 80 years. Approximately 196 million people currently live with AMD, and projections suggest 288 million cases by 2040. Wet AMD contributes to nearly 80% of severe vision impairment cases despite accounting for 10% to 15% of total AMD cases. Nearly 65% of treated patients require injections beyond 2 years. This demographic expansion directly supports Macular Degeneration Treatment Market Growth and strengthens Macular Degeneration Treatment Market Forecast across developed and emerging regions.

RESTRAINT

Treatment burden and adherence limitations.

Approximately 30% of patients discontinue therapy within 24 months. Around 25% miss at least 1 scheduled injection annually. Injection-related anxiety affects 20% of patients, although complication rates remain below 2%. In rural regions, 15% of patients lack retina specialists within a 50-mile radius. Visual acuity declines by 5–7 letters when injection intervals exceed recommended schedules. Nearly 35% of real-world patients receive fewer than 6 injections annually despite recommended 8 doses, affecting Macular Degeneration Treatment Market Analysis and treatment effectiveness.

OPPORTUNITY

Expansion of sustained-release and gene therapy solutions.

Over 15 gene therapy candidates are under clinical evaluation globally, including 5 in late-stage trials. Sustained-release implants reduce injection frequency from 8 per year to 2 per year, representing a 75% decrease in procedure burden. Approximately 45% of pipeline investments target dosing intervals beyond 12 weeks. Biosimilars increased penetration from 5% to 12% within 3 years. Emerging economies account for 35% of untreated AMD populations, representing substantial Macular Degeneration Treatment Market Opportunities for manufacturers and healthcare providers.

CHALLENGE

Clinical capacity and resource constraints.

Globally, more than 25 million injections annually require substantial infrastructure, with 1 retina specialist performing up to 2,000 injections per year. Approximately 20% of clinics report waiting lists exceeding 4 weeks. The average wet AMD patient receives 6–8 injections annually, totaling more than 20 injections over 3 years. Nearly 30% of ophthalmology departments report staffing shortages. Healthcare systems allocate up to 10% of ophthalmology budgets toward AMD care, presenting operational challenges reflected in the Macular Degeneration Treatment Industry Report.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

The Macular Degeneration Treatment Market is segmented by type into Lucentis, Eylea, Avastin, and Others, collectively accounting for over 95% of anti-VEGF prescriptions. Anti-VEGF drugs represent 85% of overall treatment utilization, biosimilars 10%, and emerging therapies 5%. By application, hospitals account for 50% of injections, eye clinics 40%, and others 10%. More than 25 million injections annually are distributed across these segments, as detailed in the Macular Degeneration Treatment Market Research Report.

By Type

Lucentis:Lucentis accounts for approximately 20% to 25% of global anti-VEGF prescriptions. Over 5 million injections are administered annually. Monthly or bi-monthly regimens result in 7–12 injections per patient per year. Clinical data show ≥15-letter visual improvement in 30% of patients at 12 months. Approved in more than 100 countries, Lucentis maintains strong penetration in 40% of European retina centers.

Eylea:Eylea holds nearly 35% to 40% of global prescriptions, representing one of the largest shares in the Macular Degeneration Treatment Market Share analysis. Over 8 million injections are delivered annually. Approximately 60% of patients transition to 8–12 week dosing after loading doses. Clinical trials report vision maintenance in 95% of patients at 1 year. Adoption exceeds 50% among retina specialists in North America.

Avastin:Avastin represents approximately 25% to 30% of global use due to cost considerations. Nearly 6 million injections are performed annually for AMD. Studies indicate comparable outcomes in 90% of patients at 12 months. In public healthcare systems, Avastin accounts for up to 40% of injections. Biosimilar expansion increased availability by 15% in Asia-Pacific markets.

Others:Other therapies account for 5% to 10% of prescriptions, including newer biologics and sustained-release implants. Gene therapy aims to reduce injections by 70% to 80% annually. Over 10 investigational drugs are in Phase II or III trials. Around 20% of advanced retina centers are participating in clinical programs involving emerging agents.

By Application

Hospitals:Hospitals manage approximately 50% of injections globally. Around 70% of advanced AMD cases are initially treated in tertiary hospital settings. Over 60% of hospital ophthalmology departments use high-resolution OCT systems exceeding 50,000 A-scans per second. Hospitals treat nearly 80% of injection-related complications.

Eye Clinics:Eye clinics perform 40% of injections worldwide. Retina specialists in outpatient settings conduct up to 2,000 injections annually. Approximately 90% of clinic visits include OCT imaging. Private eye clinics account for 55% of biosimilar prescriptions in urban regions.

Others:Other facilities represent 10% of procedures, including ambulatory centers performing 500 injections annually per facility. Clinical research institutions manage more than 15 gene therapy trials. Telemedicine programs identify AMD in 18% of screened individuals above 60 years, increasing referral rates by 25%.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

• North America: 40% share with over 8 million annual injections.
• Europe: 30% share with 6 million annual injections.
• Asia-Pacific: 22% share with 7 million diagnosed cases.
• Middle East & Africa: 8% share with 15% injection growth since 2023.

North America

North America accounts for approximately 40% of the global Macular Degeneration Treatment Market Size. The United States performs over 6 million injections annually, while Canada contributes approximately 500,000 procedures. AMD prevalence among individuals above 80 years exceeds 12%. Approximately 75% of retina specialists adopt extended dosing regimens. Biosimilars account for 15% of prescriptions. Over 80% of eligible patients receive insurance-supported treatment. More than 2,000 retina clinics operate in the region, each serving 1,500 AMD patients on average.

Europe

Europe represents around 30% of global Macular Degeneration Treatment Market Share, with 6 million injections annually. Germany, France, Italy, Spain, and the UK contribute nearly 70% of regional demand. AMD prevalence in individuals above 75 years exceeds 15%. Biosimilar penetration reached 18% by 2025. Approximately 85% of diagnosed wet AMD patients receive anti-VEGF therapy within 3 months of diagnosis.

Asia-Pacific

Asia-Pacific accounts for 22% of the global Macular Degeneration Treatment Market Outlook, with more than 7 million diagnosed cases. China and Japan represent nearly 55% of regional volume. Injection volumes increased by 25% between 2022 and 2025. Biosimilars represent 20% of prescriptions in India and South Korea. Urban retina clinics perform over 1,200 injections annually per physician.

Middle East & Africa

Middle East & Africa contribute 8% of the Macular Degeneration Treatment Market Share. AMD prevalence among individuals above 65 years ranges between 6% and 8%. Injection volumes increased by 15% between 2023 and 2025. Biosimilar adoption reached 22% in select Gulf countries. Approximately 30% of ophthalmology centers upgraded imaging systems within 3 years.

List of Top Macular Degeneration Treatment Companies

• Bausch Health Companies
• Allergan
• Novartis
• Pfizer
• Bayer
• Roche
• Sanofi
• Santen Pharmaceuticals
• Regeneron Pharmaceuticals
• Kanghong Pharma

Top 2 companies with highest market share: Regeneron Pharmaceuticals and Novartis collectively account for approximately 45% of global anti-VEGF prescription volume, with distribution across more than 80 countries and over 14 million combined annual injections.

Investment Analysis and Opportunities

Ophthalmology-focused R&D spending increased by 20% between 2023 and 2025, with 50% allocated to retinal disorders. More than 15 gene therapy programs are active globally. Manufacturing capacity expansions increased biologic output by 18% within 2 years. Approximately 40 countries introduced reimbursement adjustments supporting AMD therapy access. Venture funding directed toward sustained-release technologies accounts for 35% of retinal therapeutic investments. Emerging markets represent 35% of untreated AMD populations, offering significant Macular Degeneration Treatment Market Opportunities.

New Product Development

Between 2023 and 2025, 5 extended-release anti-VEGF formulations entered Phase III trials. Sustained-delivery systems demonstrated injection frequency reductions of up to 75%. Biosimilar launches increased by 25% in Asia-Pacific. Gene therapy candidates achieved 12-month VEGF suppression in early-phase trials. Approximately 30% of pipeline drugs aim for dosing intervals of 16 weeks or longer.

Five Recent Developments (2023–2025)

1. In 2023, Regeneron expanded production capacity by 15% to meet injection demand.
2. In 2024, Novartis increased extended dosing adoption by 20% across 25 markets.
3. In 2024, Bayer expanded distribution to 10 additional emerging markets.
4. In 2025, Roche advanced a bispecific antibody into Phase III trials involving over 1,000 patients.
5. In 2025, Kanghong Pharma increased biosimilar output by 18% for 12 regional markets.

Report Coverage of Macular Degeneration Treatment Market

The Macular Degeneration Treatment Market Report evaluates over 50 countries, analyzing 20 approved therapies and 30 pipeline assets. The Macular Degeneration Treatment Industry Analysis incorporates more than 25 million annual injections and 196 million diagnosed cases globally. Segmentation covers 4 product categories and 3 application segments. Regional analysis includes North America (40%), Europe (30%), Asia-Pacific (22%), and Middle East & Africa (8%). Clinical datasets from over 10,000 trial participants are integrated. The Macular Degeneration Treatment Market Research Report presents quantitative metrics including injection frequency per patient, biosimilar penetration rates, demographic distribution above 65 years, and facility-level treatment capacity, delivering comprehensive Macular Degeneration Treatment Market Insights for B2B decision-makers.